The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. [electronic resource]
Producer: 20130827Description: 53-64 p. digitalISSN:- 1432-0843
- Aged
- Aged, 80 and over
- Alanine -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Carcinoma, Hepatocellular -- blood
- Cohort Studies
- Dose-Response Relationship, Drug
- Female
- Half-Life
- Hepatic Insufficiency -- blood
- Humans
- Liver -- drug effects
- Liver Neoplasms -- blood
- Male
- Metabolic Clearance Rate
- Middle Aged
- Patient Dropouts
- Prodrugs -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Receptors, Fibroblast Growth Factor -- antagonists & inhibitors
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Severity of Illness Index
- Triazines -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.